ONKURE

OnKure is committed to the discovery and development of best-in-class precision medicines that target biologically validated drivers of cancer. As a team of veterans with a track record of successful drug discovery and development, we are leveraging our proven structure-based drug design approach to create a robust pipeline of drug candidates that are designed to achieve optimal tolerability and efficacy. OnKure is currently developing its lead clinical candidate OKI-179, an oral Class I HDAC inhibitor, for the treatment of both hematological and solid tumors, as well as exploring other validated oncology targets and pathways. In the evolving landscape of precision oncology, our successful tumor-agnostic approach is key to discovering new treatments for cancer patients with unmet medical needs... OnKure Therapeutics - Writing the Next Chapter in Precision Medicines for Patients With Cancer

Also known as: OnKure Therapeutics, OnKure, Inc.

Primary location: Boulder United States